About US
Contact us
-
Boehringer Ingelheim sees drug sales fall, says rest of the year will also be toughBoehringer Ingelheimis having a tough year with its drug business, seeing more than a 5% fall in sales in the first 6 months. The Germany-based company forecasts revenues will be down for the year as2014/8/12
-
Denmark's Forward Pharma to launch IP attack on Biogen Idec's MS superstar TecfideraBiogen Idec's ($BIIB) multibillion-sellingmultiple sclerosisdrugTecfiderais grabbing market share left and right, but Denmark's Forward Pharma says it has a plan to take on the monster seller with its2014/8/11
-
Pharma shares sink as U.S. threatens tax-inversion crackdownU.S. drugmakers have embraced the tax inversion strategy with open arms as of late, buying up foreign companies right and left and hauling overseas to take advantage of their lower rates. But U.S. off2014/8/8
-
Gilead Sciences prices Sovaldi in India at a tiny fraction of U.S. costThe $84,000 U.S. treatment price that Gilead Sciences ($GILD) is charging for itshepatitis CdrugSovaldihas elicited pleas from politicians and threats from payers, who say the U.S. healthcare system c2014/8/8
-
Sanofi enlists Emcure for cancer-drug marketing in IndiaSanofi ($SNY) hasn't wasted much time dithering in emerging markets. The company spent €39 billion on deals in emerging markets over the past four years. It now has 40 manufacturing sites in emergin2014/8/7
-
U.K. cost-effectiveness watchdog bars access to AstraZeneca's IressaBacktracking on a positive decision it made four years ago, Britain's National Institute for Health and Care Excellence (NICE) has dealt a blow to AstraZeneca ($AZN) by withdrawing its endorsement of2014/8/7
-
Roche persuades U.S. judge to toss $2M Accutane verdictRoche ($RHHBY) has emerged victorious in its quest to reverse a $2.1 million verdict by a New Jersey jury in favor of a woman who blamed the Swiss pharma's acne medAccutanefor her inflammatory bowel d2014/8/6
-
Note to Big Pharma: Discounts work. GSK price cuts score Advair a payer boostGlaxoSmithKline giantAdvairmay be reeling, but it hasn't kicked the bucket yet. And now, it's getting a payer boost that will breathe a little life into falling sales. With dismal second-quarter resul2014/8/5
-
Sanofi plots FDA app for blockbuster-to-be dengue vaccine in early 2015Sanofi's ($SNY) in line to rack up blockbuster sales after hitting a wide-open market with itsdenguevaccine, analysts predict. And company CEOChris Viehbacherthinks those sales could start rolling in2014/8/4
-
Novo Nordisk more valuable than GlaxoSmithKline? That's what investors sayWho'd have thought Novo Nordisk ($NVO) could zoom past GlaxoSmithKline ($GSK) in the pharma market value rankings? Predictable or not, that's just what's happened. AsBloombergreports, Novo shares are2014/8/1